Veracyte, Inc. (NASDAQ:VCYT) management will conduct a conference call for 2nd November 2020 at 4:30 PM Eastern Time to discuss financial results and companys performance for 3Q20.
The conference call will also be available live on the website www.veracyte.com
Earnings Expectation
Veracyte, Inc. is expected to report third quarter earnings results, after market close, on Monday 2nd November 2020. Analysts polled by Thomson Reuters anticipate third quarter loss of $ 0.21 per share from revenue of $ 23.88 million. Looking ahead, the full year loss are expected at $ 0.83 per share on the revenues of $ 105.02 million.
The Company Outlook
Full Year 2020 topline are forecasted in a range of$ 138.00 million ~ $ 142.00 million
Click Here For More Historical Outlooks Of Veracyte, Inc.
Veracyte, Inc. operates as a genomic diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier and Xpression Atlas solutions for a complex landscape in thyroid nodule diagnosis to physicians; Percepta Bronchial Genomic Classifier solution for use in lung cancer diagnosis; and Envisia Genomic Classifier solution for the diagnosis of idiopathic pulmonary fibrosis.
